

THE UNIVERSITY OF MICHIGAN  
REGENTS COMMUNICATION

ACTION REQUEST

Subject: Research Agreement between the University of Michigan and MedigenixBio, Inc.

Action Requested: Authorization to enter into Agreement

Preamble:

A statutory conflict of interest situation was identified by the Office of Research and Sponsored Projects while reviewing the Proposal Approval Form which then triggered a review by the Medical School Conflict of Interest Board. A plan for management of the possible risks associated with the conflict of interest was then developed and approved by the Board and agreed to by the parties involved.

This proposed research agreement ("Agreement") falls under the State of Michigan Conflict of Interest Statute because Professors Daniel Lawrence and Enming Joseph Su are employees of the University of Michigan ("University"), and partial owners of MedigenixBio, Inc. The law permits such an Agreement provided it is disclosed to the Board of Regents ("Regents") of the University of Michigan and approved in advance by a 2/3 vote.

Background:

Daniel Lawrence, Ph.D., a Professor of Cardiovascular Medicine in the Department of Internal Medicine, and Enming Joseph Su, Ph.D., a Research Assistant Professor in the Department of Internal Medicine, are the partial owners of a for-profit company called MedigenixBio, Inc. (the "Company"). The Company wishes to fund a project entitled "Kinetic Analysis of Enzymatic Activity" (ORSP# 16-PAF06316) in the Department of Internal Medicine, under the direction of Dr. Lawrence. The purpose of this project is to perform in vitro enzyme kinetic assays for inhibitors of the protease neutrophil elastase.

Agreement Terms:

The terms of the Agreement conform to University policy. The period of performance for the project is approximately one (1) year. The amount of funding support will not exceed \$9,920. Since research projects are often amended, this agreement includes a provision for changes in time and scope. University procedures for approval of these changes will be followed and additional conflict of interest review will be done as appropriate.


Impact of the Agreement

The Agreement will support an effort by Dr. Lawrence to use his expertise and University laboratory, as well as other University resources to understand novel serpin modulators tested in enzymatic, cell and structural experiments to determine mechanism of endpoint modulation.

Recommendations:

This matter has been reviewed and approved by the Medical School Conflict of Interest Board. In light of this disclosure and our finding that the Agreement was negotiated in conformance with standard University practices, I recommend that the Board of Regents approve the University's entering into this Agreement with MedigenixBio, Inc.

Respectfully submitted,



S. Jack Hu  
Vice President for Research

June 2016